CMCS-Beijing: Chinese Multi-provincial Cohort Study-Beijing Project

Sponsor
Beijing Institute of Heart, Lung and Blood Vessel Diseases (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04253054
Collaborator
(none)
3,000
3
5.7
1000
173.9

Study Details

Study Description

Brief Summary

The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiovascular risk factors
  • Other: Aging related health problems

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Chinese Multi-provincial Cohort Study-Beijing Project
Actual Study Start Date :
Sep 7, 2020
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Mar 1, 2021

Outcome Measures

Primary Outcome Measures

  1. All fatal and nonfatal acute coronary and stroke events [From date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 years]

    Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths. Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.

Secondary Outcome Measures

  1. New-onset of coronary events [From date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 years]

    Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths.

  2. New-onset of stroke [From date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 years]

    Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.

  3. Total death [From date of enrollment until date of death from all cause, assessed at least 5 years]

    All cause death

  4. Cognitive dysfunction [From date of enrollment until date of first documented event, assessed at least 5 years]

    Cognitive dysfunction

  5. Olfactory Disorders [From date of enrollment until date of first documented event, assessed at least 5 years]

    Olfactory Disorders

  6. Valvular disease [From date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 years]

    Valvular disease

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participants from CMCS-Beijing

  • sign the informed consent

Exclusion Criteria:
  • participanting in clinical trials

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Sijiqing Hospital, Beijing Beijing China
2 Peking University Hospital, Beijing Beijing China
3 Peking University Shougang Hospital Beijing China

Sponsors and Collaborators

  • Beijing Institute of Heart, Lung and Blood Vessel Diseases

Investigators

  • Principal Investigator: Jing Liu, MD, PhD, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beijing Institute of Heart, Lung and Blood Vessel Diseases
ClinicalTrials.gov Identifier:
NCT04253054
Other Study ID Numbers:
  • CMCS-Beijing 2020
First Posted:
Feb 5, 2020
Last Update Posted:
Dec 4, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 4, 2020